Reardon Andrew sold $152K of LGND
Reardon Andrew (CLO & Secretary) sold 677 shares of LIGAND PHARMACEUTICALS INC (LGND) at $225.20 ($0.15M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Because the sale is pre-arranged, it is typically less informative about near-term company prospects; the main trading use is to update insider-activity dashboards and watch for follow-on disclosures.
Market read
Low incremental information for fundamental valuation; modest relevance for sentiment/positioning only.
What to watch
Compare this sale to prior insider transactions (frequency, total net selling, and whether plans are being amended/terminated) to judge whether this is routine diversification vs. a pattern.
Background
The article is an SEC Form 4 insider transaction disclosure for Ligand Pharmaceuticals, showing an officer’s open-market sale executed under a pre-arranged 10b5-1 plan.
Ticker impact
Ligand Pharmaceuticals officer Andrew Reardon sold 677 shares in an open-market transaction under a pre-arranged 10b5-1 plan, disclosed via Form 4.
Likely limited near-term impact; treat as low-signal unless followed by additional unusual insider activity.
The filing provides a specific sale size and price but does not indicate new fundamentals; 10b5-1 plans are designed to mitigate timing-based information effects.
Market effects
Minimal—single-company insider transaction with no stated operational or regulatory change.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with internal risk assessments; monitor for clustering of sales or larger-than-usual reductions.
Key entities
- issuerLigand Pharmaceuticals Inc
Subject of the SEC Form 4 insider transaction (LGND).
- insiderAndrew Reardon
Officer (CLO & Secretary) who sold 677 shares under a 10b5-1 plan.
